Study of a diabetes drug on heart changes in diabetic patients
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a type of diabetes medication called an SGLT2 inhibitor can improve the structure and function of the heart's left atrium in people with type 2 diabetes. It may help prevent heart problems in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes and are taking diabetes medication that is not an SGLT2 inhibitor.
- Your average blood sugar level (HbA1c) is 7% or lower.
- You are between 40 and 75 years old.
- Your heart rhythm is normal (sinus rhythm).
- You have not had atrial fibrillation, a heart attack, or certain heart procedures.
- Your kidney function is good (eGFR above 30).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
This study looks at whether certain diabetes medicines, called SGLT2 inhibitors and GLP-1 receptor agonists, can help protect the heart in people with type 2 diabetes. It may help you understand if these treatments are a good option for your heart health.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
This study tests whether a heart medication (SGLT2 inhibitor) affects fat around the heart's arteries in people who have had a heart attack but do not have diabetes or heart failure. It uses a CT scan to measure changes over time.
Hear when a new SGLT 2 Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.